Navigation Links
Lung Cancer Foundation of America Gives the Gift of Life This Holiday Season: Announces Inaugural $125,000 Scientific Research Grant
Date:12/22/2009

Lung cancer, the nation’s leading cause of cancer deaths for women and men remains the most under-funded, under-researched and under-supported cancer. There are currently no approved early detection tests for lung cancer. With a 5-year survival rate of only 15%, the prognosis for lung cancer has not changed in 40 years. A new organization, Lung Cancer Foundation of America (LCFA) is trying to change this reality, and save lives by dramatically increasing the five-year survival rate for all stages of lung cancer. LCFA will accomplish this by providing the necessary and critical funding for creative and leading edge lung cancer research programs. This Holiday Season, LCFA is giving the gift of life and hope by announcing its inaugural $125,000 scientific research grant in partnership with the International Association for the Study of Lung Cancer (IASLC).

Los Angeles, CA (PRWEB) December 22, 2009 -- Lung cancer, the nation’s leading cause of cancer deaths for women and men remains the most under-funded, under-researched and under-supported cancer. There are currently no approved early detection tests for lung cancer. With a 5-year survival rate of only 15%, the prognosis for lung cancer has not changed in 40 years. A new organization, Lung Cancer Foundation of America (LCFA) is trying to change this reality, and save lives by dramatically increasing the five-year survival rate for all stages of lung cancer. LCFA will accomplish this by providing the necessary and critical funding for creative and leading edge lung cancer research programs.

As an organization barely two years old, LCFA is proud to partner with the International Association for the Study of Lung Cancer (IASLC) in announcing its inaugural Request for Proposal (RFP) for a research award in the amount of $125,000.00.    LCFA and IASLC are partnering to fund exciting research opportunities for molecular analysis of bio-specimens (blood, tissue, urine, etc.) collected as part of medium to large clinical trials. The focus will be on molecular features of tumors of patients, which will help in the selection of patients in need of therapy, and selection of optimal therapies for this subset of patients. The objectives of this RFP are to foster collaboration and interaction between basic researchers and clinical investigators to perform clinical translational research on promising predictive and prognostic markers. These studies should focus on clinical correlative or mechanistic studies that will be useful for cancer risk assessment, early detection, prognosis, and predicting response to therapy. Applications are due January 31, 2010. Applicants should be faculty members in the first 5 years of their faculty appointment, and need to explicitly define a senior mentor and mentoring plan as part of the proposal.

“I am proud to announce our new collaboration with LCFA providing a $125,000 grant opportunity for innovative lung cancer research,” said Paul Bunn, Executive Director of IASLC. “It is true that lung cancer research funding is not sufficient to cover the opportunities available nor to advance the field at the rate patients need. By working together we can indeed make an impact.”

LCFA is one of only a handful of private foundations devoted to the research of early detection and treatment of lung cancer. People assume that lung cancer research is well-funded – what they don’t realize is that most funding is earmarked for tobacco cessation and prevention programs, as well as other programs unrelated to lung cancer, and very little public and private funds actually go toward lung cancer research. As of 2006, there were less than 30 lung cancer specific foundations providing lung cancer research grants, all of which combined did not give more than $5 million dollars in grant money. At the same time, this year, lung cancer will claim more lives than breast, prostate, colon, liver, kidney and melanoma cancers – COMBINED, all of which underscores the importance of this grant and others like it.

About LCFA:
LCFA was established by two lung cancer survivors and a lung cancer widow. Although their life experiences vary greatly the three of them have come to the same realization…the poor survival rate for lung cancer is a direct result of the lack of funding for lung cancer research. Working with many of the top lung cancer researchers and clinicians in this country, LCFA has seen how lung cancer researchers are trying diligently to unlock the secrets unique to lung cancer. They have also witnessed the inordinate amount of time researchers spend in an effort to secure money to pay for the research, an effort that distracts them from their primary research function. The abysmal state of funding for lung cancer research also discourages new researchers who, instead, gravitate to where the money is, leaving a potential gaping hole in future lung cancer research programs. LCFA's mission is to save lives by dramatically increasing the five-year survival rates for all stages of lung cancer, the nation's leading cause of cancer deaths for both men and women. LCFA will accomplish this by providing the necessary and critical funding for creative and leading edge lung cancer research programs. http://lcfamerica.org/

About IASLC:
The purpose of IASLC is to promote the study of the etiology, the epidemiology, the prevention, the diagnosis, the treatment, and all other aspects of lung cancer and disseminate information about lung cancer to the members of the Association, to the medical community at large, and to the public. http://www.iaslc.org/

For more information contact Rachel Schwartz, PR AdvantEDGE Inc. http://pr-a.biz/

###

Read the full story at http://www.prweb.com/releases/LCFA/giftofliferesearchgrant/prweb3375474.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Elevated-risk women refuse MRI breast cancer screening
2. Urinary tract cancer associated with Chinese herbal products containing aristolochic acid
3. Exposing the Double Standard of the Forgotten Cancer: Biggest Cancer Killer for Women and Men, Lung Cancer, Receives Least Research Funds
4. Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry
5. Lung Cancer Alliance Hails New Federal Funding for Lung Cancer Research
6. Natural Heart Drugs May Combat Colon Cancer
7. Aggressive Infection Control Program Protects Cancer Patients from Acquiring Clinic-Based H1N1 Influenza
8. Researchers at the John Theurer Cancer Center Present Cutting-Edge Research Results at this Years American Society of Hematology Annual Meeting
9. Research suggests link between infertility, low egg reserve, and breast/ovarian cancer gene (BRCA1)
10. Protein Examined for Role in Liver Cancer
11. Spiritual Needs Rank High as Death From Cancer Nears
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 2016 , ... This campaign aims to provide a path to improved education ... control and change. , As nearly 795,000 Americans suffering from a new or recurrent ... Plus, with an estimated 129,000 of these people dying from stroke, it’s become our ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and employees ... stories, courtesy of leaders in the nursing and health care industry. It also ... advocates and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media reports ... Yellen and company to wait until March 2017 for an interest rate increase, according ... Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts are ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... and clinical outcomes, hosted members and suppliers for its inaugural Member Conference at ... on their mission of elevating the operational health of America’s healthcare providers. , ...
(Date:5/26/2016)... Florida (PRWEB) , ... May 26, 2016 , ... ... House® Project offering a new model of care for living and healing, celebrated ... core values: Meaningful Life in a Real Home provided by Empowered Staff. , “This ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... Amarantus BioScience Holdings, Inc. ... Regenerative Medicine, Neurology and Orphan Diseases, today announced that President & ... upcoming investor conferences: SeeThru Equity MicroCap Conference   ... New York City , NY When: Tuesday, May ... Conference   Where: Grand Hyatt Hotel, 109 East 42 ...
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... , Germany and GERMANTOWN, ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: ... licensing and co-development agreement with Therawis Diagnostics GmbH to develop ... be to develop and market PITX2 as a marker to ... high-risk breast cancer patients. "We are pleased to ...
Breaking Medicine Technology: